Discussions around healthcare spending have been ignored for decades, but Robert Dubois, MD, PhD, chief science officer and executive vice president at National Pharmaceutical Council, believes we have the ability to start those discussions now.
Discussions around healthcare spending have been ignored for decades, but Robert Dubois, MD, PhD, chief science officer and executive vice president at National Pharmaceutical Council, believes we have the ability to start those discussions now.
Transcript
In the United States we have typically avoided difficult healthcare spending discussions. How vital are these discussions and why do you believe they can be done?
Well, I think it’s vital that we begin to have a discussion around healthcare spending. We’ve kicked the can down the road for several decades now and problems are getting worse and worse. Whether you look at the percentage of GDP that’s spent on healthcare—if you look at the cost of health premiums—if you look at the impact of premiums on wages, whether states can provide funds for education or road repair. All of these things are crowding out because of what’s going on in the healthcare spending arena. The problem also is that the longer we delay, the more draconian the changes and the interventions are going to need to be. Medicare trust fund is going to expire in the next 6-8 years and the types of changes that are going to be required are going to be really tough if we push this off much further. Now, the next obvious question is can we actually talk about tough issues like healthcare spending—I actually believe we can. We’ve begun a series of town hall dialogues in local communities. We’ve had 1 in Nashville and 1 in Raleigh and we’ve brought local people together to talk about healthcare spending and the issues related to that—and we’ve got 6 more of these queued up. So, I'm actually quite optimistic that we can have the discussion and I’m absolutely convinced that we must have the discussion.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Mental Health Awareness: Transforming Workplace Support and Engagement
May 20th 2025Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More